Chemorefractory extranodal nasal-type natural-killer/T-cell lymphoma with great response to pembrolizumab in a young patient: a case report

Table 1 Cases previously treated with programmed cell death protein 1- programmed death ligand 1 blockers

Study	Sex	Age	Relapse sites	Stage	ECOG	Previous treatment	Treatment	Response	Outcome	Survival months
Kwong et al. [1]	M	68	Calf skin	IE	1	SIMPLE	Pembrolizumab	Metabolic and clinical CR	Continuous CR	4+
	M	49	Liver, spleen	IV	1	SMILE	Pembrolizumab	PR	Died of infection	6
	M	38	Nasopharynx, hard palate	IV	2	m-BACOO	Pembrolizumab	Clinical, molecular, and metabolic CR	Continuous CR	10+
	M	50	Liver	IV	3	GELOX	Pembrolizumab	Morphological and radiological CR	Continuous CR	8+
	M	31	Nasal cavity, liver	IV	2	SMILE	Pembrolizumab	Could not be assessed	Died of sepsis consequent on gastric bleeding	2
	M	35	Lung, esophagus	IV	2	SMILE	Pembrolizumab	CR	Continuous CR	9
	M	51	Liver	IV	1	SMILE	Pembrolizumab	CR	Continuous CR	3
Chan et al. [2]	M	59	Cerebellum and dorsal midbrain	IV	3	SIMPLE	Nivolumab	Clinical and radiological CR	Died of infection	1
	M	43	Jejunum, mesenteric lymph node	II	0	SMILE	Nivolumab	Radiological CR	Continuous CR	42
	F	80	Skin, lymph node, liver, spleen, marrow	IV	4	SIMPLE	Nivolumab	Pathological CR	Died of infection	3

CR, complete response; ECOG, Eastern Cooperative Oncology Group; GELOX, gemcitabine, l-asparaginase, and oxaliplatin; m, male; m-BACOD, methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone; SIMPLE, dexamethasone, ifosfamide, gemcitabine, cisplatin, l-asparaginase, and etoposide; SMILE, dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide

ISSN: 1752-1947